Answers are grounded in this paper and cite their sources.
The experts of the Department for Medicine Safety Evaluation of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of international pharmacovigilance regulatory authorities on the necessary labelling updates. The analysis revealed 16 decisions containing safety updates for the following medicines registered in Russia: avatrombopag, amphotericin B, acetazolamide, belimumab, bendamustine, hydrocortisone, dabrafenib, dexamethasone, denosumab, ibuprofen, cortisone, prednisolone, trametinib, nilotinib, pirfenidone, and cefotaxime.
No takes yet. Share an insight, caveat, or question.
Е. В. Шубникова (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: